Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 13/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | BIRC3 | Q13489 | 8/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 8/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CASP9 | P55211 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2631846 | 0.90 | XIAP (0.45) | XIAPKDM4EBIRC3BIRC2CYP3A4 | |
| SCHEMBL23847519 | 0.90 | XIAP (0.45) | XIAPKDM4EBIRC3BIRC2CYP3A4 | |
| SCHEMBL13048262 | 0.90 | XIAP (0.45) | XIAPKDM4EBIRC3BIRC2CYP3A4 | |
| SCHEMBL2113161 | 0.90 | XIAP (0.45) | XIAPKDM4EBIRC3BIRC2CYP3A4 | |
| SCHEMBL13048244 | 0.88 | XIAP (0.38) | XIAPFAPCCKBRKDM4EBIRC3 | |
| SCHEMBL13049936 | 0.88 | XIAP (0.38) | XIAPFAPCCKBRKDM4EBIRC3 | |
| SCHEMBL2632185 | 0.88 | XIAP (0.38) | XIAPFAPCCKBRKDM4EBIRC3 | |
| SCHEMBL2632188 | 0.84 | XIAP (0.40) | XIAPBIRC3BIRC2CYP3A4CASP9 | |
| SCHEMBL2631845 | 0.81 | ITGB3 (0.39) | CASP9 | |
| SCHEMBL2117039 | 0.81 | ITGB3 (0.39) | CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2434889-B1 | IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2016-03-09 | — | — | EP | disclosed |
| US-20130274278-A1 | IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2013-10-17 | — | — | US | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274278-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | XIAP 1/4885FAP 18/4885CCKBR 1512/4885 |
| US-20120094917-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | XIAP 1/4885FAP 18/4885CCKBR 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.